{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:01:28Z","timestamp":1792213288332,"version":"4.4.0"},"reference-count":48,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Hyponatremia is frequently found in patients with congestive heart failure. A reduction in effective circulatory blood volume in a volume-expanded patient with decreased cardiac output is linked to a baroreceptor-mediated non-osmotic release of arginine vasopressin (AVP). The increased production of AVP and salt and water retention in the proximal and distal tubules of the kidney by humoral, hemodynamic, and neural mechanisms increase circulatory blood volume and contribute to hyponatremia. Recent studies have indicated that hyponatremia predicts the short-term and long-term prognosis of heart failure by increasing cardiac death and rehospitalization. In addition, the early development of hyponatremia in acute myocardial infarction also predicts the long-term prognosis of worsening heart failure. AVP V2 receptor antagonism may relieve water retention, but it is unknown whether the V2 receptor inhibitor, tolvaptan, improves the long-term prognosis of congestive heart failure. The newly identified natriuretic factor in renal salt wasting has the potential of improving clinical outcomes when combined with a distal diuretic.<\/jats:p>","DOI":"10.3390\/jcm12041482","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T01:48:56Z","timestamp":1676252936000},"page":"1482","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hyponatremia Associated with Congestive Heart Failure: Involvement of Vasopressin and Efficacy of Vasopressin Receptor Antagonists"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6961-2361","authenticated-orcid":false,"given":"San-e","family":"Ishikawa","sequence":"first","affiliation":[{"name":"Department of Medicine, Jichi Medical University, Shimotsuke 329-0498, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Funayama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Jichi Medical University, Shimotsuke 329-0498, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJM199908193410806","article-title":"Hormones and hemodynamics in heart failure","volume":"341","author":"Schrier","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/eurheartj\/ehl542","article-title":"Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: An analysis from the OPTIMIZE-HF registry","volume":"28","author":"Gherorghiade","year":"2007","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/archinte.1996.00440150068007","article-title":"Correlates of major complications or death in patients admitted to the hospital with congestive heart failure","volume":"156","author":"Chin","year":"1996","journal-title":"Arch. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/01.CIR.0000165065.82609.3D","article-title":"Low serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure","volume":"111","author":"Klein","year":"2005","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1253\/circj.CJ-10-0945","article-title":"Early development of hypo- natremia implicates short- and long-term outcomes in ST-elevation acute myocardial infarction","volume":"75","author":"Tada","year":"2011","journal-title":"Circ. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.amjmed.2004.03.022","article-title":"Prognostic importance of hyponatremia in acute ST-elevation myocardial infarction","volume":"117","author":"Goldberg","year":"2004","journal-title":"Am. J. Med."},{"key":"ref_7","first-page":"CR477","article-title":"Sodium level on admission and in-hospital outcomes of STEMI patients treated with primary angiopathy. The ANIN Myocardial Infarction Registry","volume":"15","author":"Klopotowski","year":"2009","journal-title":"Med. Sci. Monit."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.amjcard.2007.03.039","article-title":"Effect of hyponatremia (<135 mEq\/L) on outcome in patients with non-ST-elevation acute coronary syndrome","volume":"100","author":"Singla","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM198107303050506","article-title":"Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure","volume":"305","author":"Szatalovitz","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1042\/cs0620465","article-title":"The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure","volume":"62","author":"Riegger","year":"1982","journal-title":"Clin. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/ki.1990.276","article-title":"Arginine vasopressin gene expression in chronic cardiac failure in rats","volume":"38","author":"Kim","year":"1990","journal-title":"Kidney Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ki.1986.149","article-title":"Effect of vasopressin antagonist on water excretion in inferior vena cava constriction","volume":"30","author":"Ishikawa","year":"1986","journal-title":"Kidney Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1172\/JCI119312","article-title":"Upregulation of aqua- porin-2 water channel expression in chronic heart failure rat","volume":"99","author":"Xu","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJM198810203191606","article-title":"Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis and pregnancy (1)","volume":"319","author":"Schrier","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1056\/NEJM198810273191705","article-title":"Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis and pregnancy (2)","volume":"319","author":"Schrier","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ishikawa, S. (2017). Is exaggerated release of arginine vasopressin an endocrine disorder? Pathophysiology and treatment. J. Clin. Med., 6.","DOI":"10.3390\/jcm6110102"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/361549a0","article-title":"Cloning and expression of apical membrane water channel of rat kidney collecting tubules","volume":"361","author":"Fushimi","year":"1993","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.V891357","article-title":"Urinary excretion of aquaporin-2 water channel protein in human and rats","volume":"8","author":"Rai","year":"1997","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199506083322303","article-title":"Urinary excretion of aquaporin-2 in patients with diabetes insipidus","volume":"332","author":"Kanno","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_20","first-page":"1823","article-title":"Urinary excretion of aquaporin-2 in the diagnosis of central diabetes insipidus","volume":"82","author":"Saito","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s10157-011-0574-2","article-title":"Daily variance of urinary excretion of AQP2 determined by sandwich ELISA method","volume":"16","author":"Sasaki","year":"2012","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/j.1523-1755.2004.00902.x","article-title":"Urinary excretion of 12 aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure","volume":"66","author":"Funayama","year":"2004","journal-title":"Kidney Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/ki.1986.126","article-title":"Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure","volume":"29","author":"Bichet","year":"1986","journal-title":"Kidney Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/archinte.167.18.1998","article-title":"Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ES-CAPE Trial","volume":"167","author":"Gheorghiade","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1253\/circj.CJ-14-0752","article-title":"Arginine vasopressin in heart failure","volume":"78","author":"Ishikawa","year":"2014","journal-title":"Circ. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1253\/circj.CJ-12-0672","article-title":"Hyponatremia as a predictor for worsening heart failure in patients receiving cardiac resynchronization therapy","volume":"77","author":"Arao","year":"2013","journal-title":"Circ. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1476-5381.1992.tb09058.x","article-title":"Characterization of a aquaretic agent, OPC-31260, as an orally effective, non- peptide vasopressin V2 receptor antagonist","volume":"105","author":"Yamamura","year":"1992","journal-title":"Br. J. Pharmacol."},{"key":"ref_28","first-page":"860","article-title":"OPC-41061, a highly potent human vaso-pressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats","volume":"287","author":"Yamamura","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1681\/ASN.2009080857","article-title":"Oral tolvaptan is safe and effective in chronic hyponatremia","volume":"21","author":"Berl","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trial","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Acute and chronic therapeutic impact of a vasopressin antagonist in patients hospitalized with worsening heart failure: A randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trial","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1253\/circj.CJ-14-0126","article-title":"Efficacy and safety of tolvaptan in heart failure patients with volume overload: An interim result of post-marketing surveillance in Japan","volume":"78","author":"Kinugawa","year":"2014","journal-title":"Circ. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1253\/circj.CJ-17-0554","article-title":"Safety and efficacy of long-term use of tolvaptan in patients with heart failure and chronic kidney disease","volume":"81","author":"Uemura","year":"2017","journal-title":"Circ. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1253\/circj.CJ-19-0158","article-title":"Real-world effectiveness and tolerability of tolvaptan in patients with heart failure","volume":"83","author":"Kinugawa","year":"2019","journal-title":"Circ. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijcard.2016.07.063","article-title":"Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction","volume":"221","author":"Matsue","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1253\/circj.CJ-16-1122","article-title":"Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure and preserved left ventricular ejection fraction","volume":"81","author":"Tamaki","year":"2017","journal-title":"Circ. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jjcc.2015.04.017","article-title":"Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size","volume":"67","author":"Toda","year":"2016","journal-title":"J. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1536\/ihj.17-099","article-title":"Tolvaptan improves prognosis in responders with acute decompensated heart failure by reducing the dose of loop diuretics","volume":"59","author":"Nakamura","year":"2018","journal-title":"Int. Heart J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","article-title":"Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure","volume":"69","author":"Felker","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1177\/0300060519882221","article-title":"Tolvaptan in reversing worsening acute heart failure: A systemic review and meta-analysis","volume":"47","author":"Wang","year":"2019","journal-title":"J. Int. Med. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/qjmed\/hcn061","article-title":"Mild hyponatremia and risk of fracture in the ambulatory elderly","volume":"101","author":"Kengne","year":"2008","journal-title":"QJM"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"71.e1","DOI":"10.1016\/j.amjmed.2005.09.026","article-title":"Mild Chronic Hyponatremia Is Associated With Falls, Unsteadiness, and Attention Deficits","volume":"119","author":"Renneboog","year":"2006","journal-title":"Am. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra1404489","article-title":"Disorder of plasma sodium-causes, consequences and correction","volume":"372","author":"Sterns","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.amjms.2020.07.015","article-title":"Identification of Novel Natriuretic Protein in Patients With Cerebral-Renal Salt Wasting-Implications for Enhanced Diagnosis","volume":"361","author":"Maesaka","year":"2021","journal-title":"Am. J. Med. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Maesaka, J.K., Imbriano, L.J., and Miyawaki, N. (2022). A New Approach to Hyponatremia, High Prevalence of Cerebral\/Renal Salt Wasting, identification of natriuretic protein that causes salt Wasting. J. Clin. Med, 11.","DOI":"10.3390\/jcm11247445"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/4\/1482\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:33:00Z","timestamp":1760121180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/4\/1482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["jcm12041482"],"URL":"https:\/\/doi.org\/10.3390\/jcm12041482","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]}}}